Nonmyeloablative allogeneic stem cell transplantation (NST) is thought to be an immunologic therapy in which donor T cells mediate a graft-versus-tumor effect. We recently reported the clinical outcome of a phase II trial of NST in metastatic renal cell carcinoma (RCC). However, the immune response correlates of clinical activity remain unknown. We now describe the analysis of T-cell subsets and T-cell cytokine-producing potential for those patients evaluable for immune monitoring. The incidence of graftversus-host disease (GVHD) correlated with clinical outcome, with all responders exhibiting chronic GVHD. Following initial tapering of immunosuppression, an increase in the total numbers of CD8 þ T cells but not CD4 þ T cells was observed among responders compared to nonresponders. In addition, a greater ratio of CD8 þ to CD4 þ T cells producing IFN-c and IL-2 was seen in clinical responders at the time when clinical responses were first detected (day 180 after transplantation). Our results support the hypothesis that the antitumor effects of NST may be mediated by IFN-c-producing CD8 þ T cells, and indicate that isolation of putative tumor antigen-specific T cells, ideally, should be pursued around day þ 180.
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Metastatic renal cell carcinoma (RCC) remains poorly responsive to chemotherapy. 1 However, it is one of the solid tumors that has demonstrated responsiveness to immune-based interventions. Cytokines such as interferon-a and interleukin-2 are among the most active agents against RCC, albeit with modest response rates of around 15% with complete responses in 3-5% of patients. 2 Administration of in vitro expanded lymphocytes also induces responses in a minority of patients, although it has shown a survival benefit only in one study. 3 Allogeneic hematopoietic stem cell transplantation has been shown to provide a potent immune therapy against hematologic malignancies through a graft-versus-leukemia (GVL) effect. [4] [5] [6] By extension, a graft-versus-tumor (GVT) effect, similar to GVL, has been suggested to occur in preclinical models through recognition of minor histocompatibility antigens. 7 Effectiveness of this therapy must be counterbalanced by significant morbidity and mortality, especially with traditional intensive conditioning regimens. Using a nonmyeloablative conditioning regimen for allogeneic stem cell transplantation (NST), a broader group of patients can safely be transplanted through a reduction in acute transplant-related mortality. NST for RCC has demonstrated impressive clinical activity, with response rates of 33-50% in patients who have failed initial immunotherapy. [8] [9] [10] [11] [12] The correlation of graft-versus-host disease (GVHD) with clinical response and the fact that responses usually develop around 4 months after transplant, when full hematopoietic engraftment and tapering of immunosuppression have occurred, support the hypothesis that antitumor activity is mediated by a GVT effect. 13 Analysis of T cells from patients following allogeneic stem cell transplant for hematologic malignancies has enabled an initial characterization of candidate antigens that mediate the therapeutic GVL effect. 14 The existence of these minor histocompatibility antigen-specific T-cell responses lends further support for an immunologic mechanism underlying the success of this treatment. However, the immunologic events that correlate with clinical response in NST for RCC are not known. Understanding the general characteristics of T-cell responsiveness in clinical responders vs nonresponders should point to the subsets of cells to analyze for tumor antigen specificity, and should also highlight at what time point such T cells should be sought. We therefore enumerated T-cell subsets and analyzed T-cell cytokine-producing potential in a cohort of patients treated with NST for advanced RCC.
Patients and methods

Treatment protocol
The protocol was approved by the University of Chicago Institutional Review Board and has been described. 10 Briefly, all donors and transplant recipients signed written informed consent. In all, 16 NSTs were performed in 15 interferon-alpha and/or interleukin-2 refractory patients from 6/6 HLA-matched siblings (one patient received a second transplant from a different sibling and another patient received a transplant from a 5/6 HLA-matched sibling). The first four patients were conditioned with fludarabine (30 mg/m /day i.v. on day À3 and day -2, 4 g/m 2 total of cyclophosphamide), permitting stable donor engraftment with the 12 subsequent transplants. Peripheral blood progenitor cells were mobilized from the HLA-matched donor with granulocyte-colony-stimulating factor (G-CSF) at 16 mg/kg daily, and collected on day þ 5 with a cumulative harvest of at least 3.0 Â 10 6 CD34 þ cells/kg of recipient weight. Post-transplant immunosuppression employed tacrolimus (FK506) from day À1 to day 90, maintaining levels of 5-15 ng/ml, and mycophenolate mofetil (MMF) 1 g orally twice daily from day 0 to day 60. MMF was stopped at day 60, while tacrolimus was tapered slowly from day 90 to day 110. Early tapering of immunosuppression was not performed, even for progressive disease or early complete donor chimerism. However, treatment of GVHD was at the discretion of the treating physician. Thus, institution of corticosteroids, or resumption of tacrolimus or MMF, was permitted for management of GVHD. Engraftment was measured by chimerism analysis of peripheral blood mononuclear cells, using fluorescence in situ hybridization for patients with donors of the opposite sex and variable number of tandem repeats analysis by polymerase chain reaction for patients with same-sex donors. 10 In some cases, purified CD8 þ T cells were used to assess engraftment in addition to total peripheral blood mononuclear cells. 10 All patients except patient 4b had 100% engraftment by day þ 180, and thus had 100% donor-derived T cells at that time. Responses were assessed by computerized tomography scanning on day þ 30, day þ 100, and every 3 months thereafter.
Flow cytometric analysis
Recipient immune reconstitution was assessed from the peripheral blood by flow cytometry starting at day þ 90 after transplantation. Lymphocyte subsets were enumerated using blood counts and differential analysis performed by the University of Chicago clinical hematology laboratory in combination with flow cytometry. To calculate the numbers of CD8 þ T cells, the total number of lymphocytes per microliter of blood was multiplied by the fraction of CD8 þ cells found among the CD3 þ population of lymphocytes, as determined by surface staining with PerCP-conjugated anti-CD3 and FITC-conjugated anti-CD8. To calculate the numbers of CD4 þ T cells, the total number of lymphocytes per microliter of blood was multiplied by the fraction of CD8 À cells found among the CD3 þ population of lymphocytes. The lymphocyte population was gated based on size and granularity.
Intracellular cytokine staining
Whole blood was centrifuged and plasma was removed from the cells. Blood cells were resuspended in RPMI medium with L-glutamine (2 mM) and monensin (2 mM). Half the sample was activated to induce T-cell cytokine production by addition of PMA (40 ng/ml) and ionomycin (1.6 mg/ml); the other half was set aside as a resting control. Cells were incubated for 4 h at 371C, and were then stained with FITC-conjugated anti-CD8 and PerCP-conjugated anti-CD3. The RBCs were lysed with FACS Lysing Solution (BD Biosciences, San Jose, CA, USA). The remaining cells were washed, permeabilized, and stained for intracellular cytokines using PE-conjugated anti-IL-2, anti-IL-4, or anti-IFN-g. All antibodies were purchased from BD Biosciences (San Jose, CA, USA). Data were acquired using a þ and cytokine by the number of total CD8 þ T cells, calculated as described above. The number of CD4 þ T cells producing cytokine was determined by multiplying the fraction of CD3 þ cells staining negative for CD8 þ and positive for cytokine by the number of total CD4 þ T cells, calculated as described above. The absolute number of cytokine-producing cells for either subset was calculated by deducting the number of cytokine-producing cells seen in the resting sample (background staining) from the number of cytokine-producing cells seen in the activated sample.
Statistical analysis
Enumeration of lymphocyte subsets and cytokine-producing T cells was performed in a blinded fashion, such that the clinical outcome for each patient was not unblinded until the time of statistical analysis. Correlation between GVHD and clinical response was assessed using a twotailed Fisher's exact test. Comparisons between clinical responders and nonresponders were made using an unpaired t-test. All analyses were performed using SPSS software.
Results
Patients analyzed for immunologic parameters
In our series of 15 RCC patients treated with NST, there was an overall response rate of 27%, 33% in those achieving stable donor engraftment. All patients who
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þ T-cell expansion in NST for kidney cancer H Harlin et al received the higher dose-conditioning regiment achieved 100% donor chimerism within 180 days. Of note, one patient (patient #4) initially experienced graft failure, but later received a second NST using the modified conditioning regimen and achieved complete donor hematopoietic engraftment. Clinically, there were four partial responses and the remaining participants experienced stable or progressive disease. All of the responding patients remain alive to date, more than 2 years since transplantation. Immunologic parameters were not analyzed until after day þ 90, since high levels of immunosuppression would inhibit T-cell function. Out of the 14 patients with stable engraftment, six died within 5 weeks of transplantation and one patient did not have sufficient blood samples obtained to allow for analysis. The remaining seven evaluable patients are shown in Table 1 . Patient 4a denotes the first transplantation of patient 4, when engraftment eventually failed, and patient 4b denotes the second transplantation of patient 4 from a different donor. There were thus four patient treatments associated with a clinical response and four associated with progressive disease, that were analyzed for immunologic parameters.
Incidence of GVHD
Clinical responses were not observed until after the post transplant immune suppression was initially tapered. These responses were detected at the time of clinical re-evaluation performed at approximately day þ 180. Furthermore, all of the patients who had clinical responses also had chronic extensive GVHD, whereas only one of the nonresponders exhibited GVHD. This observation was of borderline statistical significance (P ¼ 0.071; Table 1), and suggests that an alloimmune response is associated with tumor regression.
T-cell subsets among responders and nonresponders
CD8
þ T cells are thought to be the main cytolytic effectors in antitumor responses, whereas CD4 þ T cells provide help towards establishing these responses. The fractions of CD4 þ and CD8 þ T cells present in peripheral blood were thus determined by flow cytometric analysis, and absolute numbers of CD4 þ and CD8 þ T cells were calculated and analyzed among clinical responders and nonresponders. As shown in Figure 1 , although the mean number of total CD3 þ T cells was similar among the two groups at the time of clinical response (day þ 180), the responders showed a larger number of CD8 þ compared to CD4 þ T cells. This difference was most striking when the CD8/CD4 ratio was examined, which was approximately 3:1 (Figure 1d ). The ratio was reversed compared to the normal CD8/CD4 ratio of approximately 0.5, which we confirmed using our methodology in a series of normal donors (data not shown).
As it was conceivable that a difference in the kinetics of expansion of T-cell subsets between patients could have explained this result, the numbers of CD8 þ and CD4 þ T cells and also the CD8/CD4 ratio were examined over time. As shown in Figure 2 , the higher proportion of CD8 þ T cells in responders compared to nonresponders was preserved during the period after tapering of immunosuppression (day þ 90). As the hematopoietic cells were of 100% donor origin at this time, 10 
Cytokine-producing profiles of responders and nonresponders
IFN-g secretion by T cells has been linked to cytolytic antitumor effects in murine models in vivo. 15, 16 . IL-2 is mainly produced by CD4 þ T cells and is an important component of T-cell help, 17, 18 although CD8 þ T cells can produce IL-2 as well. 19 We hypothesized that the presence of IFN-g-producing CD8
þ T cells and/or IL-2-producing CD4 þ T cells might correlate with a favorable clinical outcome. The cytokine-producing capability of T-cell subsets following NST was assessed using intracellular FACS analysis for IFN-g, IL-2, and IL-4, and the absolute number of cells producing each cytokine was determined at each time point. A representative flow cytometric analysis is shown in Figure 3 . The mean values were calculated for CD4 þ and CD8 þ T cells, and were compared in clinical responders versus nonresponders at day þ 180.
As shown in Figure 4 , a modestly increased number of IFN-g-producing CD8
þ T cells, and a decreased number of IFN-g-producing CD4
þ T cells, was observed among Patients who had clinical responses are shown in the upper half. The incidence and nature of clinical response, time of response, and the incidence and severity of chronic GVHD (cGVHD) are shown. The incidence of GVHD among responders and nonresponders was of borderline significance (P ¼ 0.071). Disease site abbreviations are: Lu, lung; K, kidney or renal fossa; Liv, liver; soft, soft tissue mass; LN, lymph node; Ad, adrenal. PR, partial response; PD, progressive disease.
clinical responders compared to nonresponders. This reached statistical significance when the CD8/CD4 ratio was examined (P ¼ 0.042; Figure 4d) . Similarly, an increased number of CD8 þ T cells, and a decreased number of CD4 þ T cells, producing IL-2 was observed among clinical responders compared to nonresponders ( Figure 5 ). This result, as for the overall number of cells, was most striking when the CD8/CD4 ratio was examined þ /CD4 þ ratio (panel (c)) were determined by flow cytometry over time between day 0 and day þ 280, and the absolute number of each subset per microliter was calculated, based on the total number of lymphocytes. For each parameter, the mean and s.e.m. were determined among responders and nonresponders at each time point.
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þ T-cell expansion in NST for kidney cancer H Harlin et al (Figure 5d ). Very few T cells of either subset producing IL-4 were observed at any time point (Figure 3 and data not shown), and these low levels had no association with clinical outcome, arguing that T cells in nonresponders did not detectably shift to a Th2 phenotype. Collectively, these results suggest that clinical responses to NST for RCC are associated with an expanded ratio of CD8/CD4 T cells producing IFN-g.
Discussion
Impressive clinical responses have been demonstrated in cytokine-refractory RCC patients undergoing NST. While this clinical activity appears to depend upon donor hematopoietic cells, the precise mechanisms by which this occurs remains undefined. It is conceivable that the tumor responses seen in the context of GVHD are mediated by nonspecific cytokine effects rather than by specific T cells. However, this is unlikely as all patients treated by NST in our study were cytokine refractory, and clinical response has occasionally been seen in the absence of GVHD. 20 Allogeneic NK cells from donor-recipient pairs mismatched for killer-inhibitory receptors (KIR) provide another potential mechanism. 21 However, KIR recognition usually occurs via HLA-C alleles, and our donor-recipient pairs were matched at HLA-C. Thus, it is likely that specific donor T cells play a critical role in mediating tumor regression.
In the present study, we observed that increased numbers of CD8 þ CD3 þ cells, and an increased ratio of IFN-gproducing CD8
þ to CD4 þ CD3 þ cells, were associated with clinical response following NST. Although the number of patients evaluable in our study is small, these observations support a likely role for IFN-g-producing CD8 þ cytotoxic T lymphocytes in mediating the GVT effect following this treatment. As we enumerated CD3
þ CD8 þ cells, we cannot rule out a potential contribution by a rare subset of CD8 þ NK T cells. It is conceivable that increased production of cytokines that drive T-cell differentiation to an IFN-g-producing phenotype, such as IL-12 or IL- 18, 22 in clinical responders might contribute to this result. This hypothesis may be worth examining in future studies. Although our analysis of immunologic parameters began after the initial tapering of immunosuppression, all the patients who developed GVHD required re-institution of some level of immunosuppressive treatment. Thus, the expansion in CD8 þ T-cell numbers and IFN-g production in responders might have been even greater if treatment for GVHD had not been required.
As all patients who attained a clinical response also displayed GVHD, it is possible that a proportion of the expanded CD8 þ T cells observed post treatment are specific for minor histocompatibility antigens with a broad tissue distribution, and thus contribute to GVHD. An increase in CD8/CD4 ratio is often observed in patients after allogeneic hematopoietic stem cell transplantation, and has been primarily attributed to decreased numbers of CD4 þ T cells, 23 but this increased CD8/CD4 ratio has not been shown to correlate with the incidence of GVHD. 24 Interestingly, in our study, the only clinical nonresponder who had extensive chronic GVHD did not exhibit an increased CD8/CD4 ratio, and also had the lowest ratio of IFN-g-producing CD8
þ to CD4 þ CD3 þ cells of any of the patients (0.38) at the time of clinical response. In fact, if the ratio of IFN-g-producing CD8
þ to CD4 þ CD3 þ cells was compared between patients with or without chronic GVHD, the difference was not statistically significant (P ¼ 0.25), arguing that the increased ratio of IFN-gproducing CD8
þ T cells may be more linked to clinical response than to incidence of GVHD.
Allogeneic bone marrow and peripheral blood stem cell transplantation for hematologic malignancies has enabled molecular identification of candidate antigens that mediate GVL vs GVHD effects. Most of these identified to date represent polymorphisms in normally expressed genes, including IFI-75, Uty, KIAA0020, and UGT2B17. , and CD3 þ (panel (c)) T cells producing IL-2 at the time of clinical response (day þ 180) were determined as described in Figure 3 . The mean and s.e.m. among responders and nonresponders were determined, and are indicated. The ratio of IL-2-producing CD8 þ T cells/IL-2-producing CD4 þ T cells was also calculated (panel (d)). The latter was a strong trend, but did not achieve statistical significance, based on an unpaired t-test (P ¼ 0.16).
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þ T-cell expansion in NST for kidney cancer H Harlin et al Some of these are highly expressed in hematopoietic cells, and may support leukemia recognition by donor T cells, whereas others are expressed in the liver and are likely targets for GVHD. It is likely that minor histocompatibility antigens and/or tumor-specific antigens that are preferentially expressed in RCC cells are dominant targets of CD8 þ T cells in our patients, identification of which will require future studies. Our data suggest that obtaining CD8 þ T cells at day þ 180 in clinical responders may provide the greatest likelihood of identifying antitumor T-cell clones.
Although it is clear that NST has clinical activity in RCC, it also carries substantial toxicity, which is predominantly a result of GVHD. Our current results suggest that donor-derived CD8 þ T cells may mediate the GVT effect of this treatment. These results should be validated in a larger prospective study. Identification of the specific T cells that mediated GVT, as well as of the antigens they recognize, should allow creation of a more specific therapy in the future, which favors GVT without GVHD.
